Cargando…

eNose-TB: A trial study protocol of electronic nose for tuberculosis screening in Indonesia

BACKGROUND: Even though conceptually, Tuberculosis (TB) is almost always curable, it is currently the world’s leading infectious killer. Patients with pulmonary TB are the source of transmission. Approximately 23% of the world’s population is believed to be latently infected with TB bacteria, and 5–...

Descripción completa

Detalles Bibliográficos
Autores principales: Saktiawati, Antonia Morita Iswari, Triyana, Kuwat, Wahyuningtias, Siska Dian, Dwihardiani, Bintari, Julian, Trisna, Hidayat, Shidiq Nur, Ahmad, Riris Andono, Probandari, Ari, Mahendradhata, Yodi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059810/
https://www.ncbi.nlm.nih.gov/pubmed/33882070
http://dx.doi.org/10.1371/journal.pone.0249689
Descripción
Sumario:BACKGROUND: Even though conceptually, Tuberculosis (TB) is almost always curable, it is currently the world’s leading infectious killer. Patients with pulmonary TB are the source of transmission. Approximately 23% of the world’s population is believed to be latently infected with TB bacteria, and 5–15% of them will progress at any point in time to develop the disease. There was a global diagnostic gap of 2.9 million between notifications of new cases and the estimated number of incident cases, and Indonesia carries the third-highest of this gap. Therefore, screening TB among the community is of great importance to prevent further transmission and infection. The electronic nose for screening TB (eNose-TB) project is initiated in Yogyakarta, Indonesia, to screen TB by breath test with an electronic-nose that is easy-to-use, point-of-care, does not expose patients to radiation, and can be produced at low cost. METHODS/DESIGN: The objectives of the two-phase planned project are to: 1) investigate the potential of an eNose-TB as a screening tool in Indonesia, in comparison with screening with clinical symptoms and chest radiology, which are currently used as a standard, and 2) analyze the time and cost of a screening algorithm with eNose-TB to obtain additional case detection. A cross-sectional study will be conducted in the first phase to validate the eNose-TB. The validation phase will involve 395 presumptive TB patients in the Surakarta General Hospital, Central Java. In the second phase, a cross-sectional research will be conducted, involving 1,383 adults and children in the municipality of Yogyakarta and Kulon Progo district of Yogyakarta Province. DISCUSSION: The findings will provide data concerning the sensitivity and specificity of the eNose-TB as a screening tool for tuberculosis, and the time and cost analysis of a screening algorithm with the eNose. TRIAL REGISTRATION: NCT04567498; https://clinicaltrials.gov/.